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Calculation Skills: Raynaud’s Phenomenon 
Raynaud’s phenomenon is a condition caused by vasospasm of the arteries which blocks the blood 
flow to the extremities, usually the fingers and/or toes but may also affect the ears, nipples, lips and 
nose (NICE, 2014). The condition can be triggered by stress, anxiety and cold temperatures (NHS 
Choices, 2015). Primary Raynaud’s refers to the condition which develops without any underlying 
cause, whilst secondary Raynaud’s is mainly caused by an underlying connective tissue disorder 
(NICE, 2014). Patient’s with Raynaud’s present with colour changes to the affected area (white, then 
blue, then red), often along with pain, numbness and pins and needles (NHS Choices, 2015). 
 
Question 1 
The prevalence of Raynaud’s phenomenon is said to be between 3% and 21% (Carpentier, 2006). 
Based on these figures: 
(i) What is the mean percentage of people affected by Raynaud’s? 
(ii) How many people in 1500 would be affected based on the lowest estimated 
percentage? 
(iii) How many people in 1500 would be affected based on the highest estimated 
percentage? 
 
Question 2 
Judy is a 39 year old social worker. After making the recommended lifestyle changes, she has not 
seen any improvement in her condition and is to be prescribed prophylactic immediate-release 
nifedipine. She is required to start with the lowest recommended dose of 5mg (JFC, 2017), three 
times daily. 5mg capsules are available at a cost of £5.73 for 90 capsules. 
(i) How many capsules will Judy need for the 16 days treatment until her next 
appointment? 
(ii) What will be the cost of this period of treatment (based on price per tablet rounded up 
or down to nearest pence) 
 
Question 3 
Due to limited response to her initial treatment, Judy’s nifedipine is increased in the weeks following 
her review appointment. She takes 10mg 3 times daily for 14 days, 15mg 3 times daily for 14 days 
and has been taking 20 mg 3 times daily for the last 7 days. Capsules are available in 5mg, 10mg, and 
20mg strengths. 
(i) How much nifedipine in total (in grams) has Judy taken since commencing the treatment 
with nifedipine? 
(ii) Assuming Judy took her nifedipine using the minimum number of capsules required to 
make up the dose, how many nifedipine capsules has she taken in total? 
 
 
Question 4 
After a period of remission, Kim (a 29 year old writer) has presented again with Raynaud’s. Due to 
suffering adverse effects from the immediate release nifedipine previously, she is to be prescribed 
modified-release off-label. She commences on the lowest recommended dose of 20mg modified-
release nifedipine once daily. 20mg capsules are available at a cost of £5.41 for 60 capsules. 
What would be the difference in cost between seven days treatment with the lowest daily dose of 
modified-release nifedipine and the lowest daily dose of immediate-release nifedipine? (Based on 
price per tablet) 
 
Question 5 
Nice (2014) advise that up to two thirds of patients being treated with nifedipine suffer adverse 
effects. Based on your answer to question 1 (ii), how many of those patients will suffer adverse 
effects from nifedipine? 
 
Answers 
Question 1 
(i) Mean percentage = (3% + 21%) ÷ 2 = 12% 
(ii) Number of people in 1500 that would be affected based on the lowest estimated 
percentage: 3% of 1500  
1% = 1500 ÷ 100 = 15 
3% = 3 x 15 = 45 
(iii) Number of people affected based on the highest estimated percentage: 21% of 1500  
21 x 15 = 315 
 
Question 2 
(i) Capsules required = 1 (capsule) x 3 (daily) x 16 (days) = 48 
(ii) Cost per capsule = £5.73 ÷ 90 =  6p (rounded down) 
Cost per 16 days = 6p x 48 = £2.88 
 
Question 3 
Due to limited response to her initial treatment, Judy’s nifedipine is increased in the weeks following 
her review appointment. She takes 10mg three for 14 days, 15mg for 14 days and has been taking 20 
mg for the last 7 days. Capsules are available in 5mg, 10mg, and 20mg strengths. 
 
(i) First 16 days = 48 x 5 = 240mg 
Next 14 days = 42 x 10 = 420 mg 
Next 14 days = 42 x 15 = 630mg 
Last 7 days = 21 x 20 = 420mg 
Total = 240 + 420 + 630 + 420 = 1710 mg / 1.710g 
 
(ii) First 16 days = 48  
Next 14 days = 42  
Next 14 days = 42  
Last 7 days = 21  
Total = 48 + 42 + 84 + 21 = 195 capsules 
 
Question 4 
Cost of modified-release capsules: 
1 day’s treatment = £5.41 ÷ 60 = 9p (rounded down)  
7 day’s treatment = 7 x 9p = 63p 
Cost of immediate-release capsules: 
1 day’s treatment = 3 x 6p = 18p 
7 day’s treatment = 7 x 18p = £1.26 
Difference in cost = £1.26 – 63p = 63p 
 
Question 5 
Nice (2014) advise that up to two thirds of patients being treated with nifedipine suffer adverse 
effects. Based on your answer to question 1 (ii), how many of those patients will suffer adverse 
effects from nifedipine? 
Total people = 45 
2/3rds = 30 
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